DK2783682T3 - Farmaceutisk sammensætning omfattende pimobendan - Google Patents

Farmaceutisk sammensætning omfattende pimobendan Download PDF

Info

Publication number: DK2783682T3
Authority: DK; Denmark
Prior art keywords: pimobendan; pharmaceutical composition; composition comprehensive; comprehensive; pharmaceutical
Prior art date: 2004-03-08

Application number

DK14171534.2T

Other languages

English (en)

Inventor

Martin Andreas Folger

Jens Lehmann

Stefan Henke

Bernhard Hassel

Original Assignee

Boehringer Ingelheim Vetmedica Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-08

Filing date

2005-03-01

Publication date

2019-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34877563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2783682(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-03-01 Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh

2019-08-12 Application granted granted Critical

2019-08-12 Publication of DK2783682T3 publication Critical patent/DK2783682T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Botany (AREA)
Biochemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Feed For Specific Animals (AREA)
Fodder In General (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Seasonings (AREA)

DK14171534.2T 2004-03-08 2005-03-01 Farmaceutisk sammensætning omfattende pimobendan DK2783682T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004011512.5A DE102004011512B4 (de)	2004-03-08	2004-03-08	Pharmazeutische Zubereitung enthaltend Pimobendan
EP05715625.9A EP1725218B1 (en)	2004-03-08	2005-03-01	Pharmaceutical composition comprising pimobendan

Publications (1)

Publication Number	Publication Date
DK2783682T3 true DK2783682T3 (da)	2019-08-12

Family

ID=34877563

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK14171534.2T DK2783682T3 (da)	2004-03-08	2005-03-01	Farmaceutisk sammensætning omfattende pimobendan
DK05715625.9T DK1725218T3 (da)	2004-03-08	2005-03-01	Farmaceutisk sammensætning omfattende pimobendan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK05715625.9T DK1725218T3 (da)	2004-03-08	2005-03-01	Farmaceutisk sammensætning omfattende pimobendan

Country Status (25)

Country	Link
US (5)	US8846679B2 (da)
EP (2)	EP1725218B1 (da)
JP (2)	JP4757253B2 (da)
KR (2)	KR20070014143A (da)
CN (1)	CN100546568C (da)
AR (2)	AR047993A1 (da)
AU (1)	AU2005218912C1 (da)
BR (1)	BRPI0508557B1 (da)
CA (1)	CA2557161C (da)
CY (2)	CY1115526T1 (da)
DE (1)	DE102004011512B4 (da)
DK (2)	DK2783682T3 (da)
ES (2)	ES2501216T3 (da)
HR (2)	HRP20140900T1 (da)
HU (1)	HUE045637T2 (da)
IN (1)	IN2014DN07624A (da)
LT (1)	LT2783682T (da)
MX (1)	MXPA06009889A (da)
NZ (1)	NZ549630A (da)
PL (2)	PL2783682T3 (da)
PT (2)	PT2783682T (da)
SI (2)	SI1725218T1 (da)
TW (1)	TWI355947B (da)
WO (1)	WO2005084647A1 (da)
ZA (1)	ZA200606154B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) *	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) *	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP2006028130A (ja) *	2004-07-21	2006-02-02	Toa Eiyo Ltd	ピモベンダン経口投与製剤
JP4572293B2 (ja) *	2004-07-21	2010-11-04	トーアエイヨー株式会社	ピモベンダン経口投与製剤
JP4572296B2 (ja) *	2004-07-21	2010-11-04	トーアエイヨー株式会社	ピモベンダン経口投与製剤
JP4572300B2 (ja) *	2006-01-19	2010-11-04	トーアエイヨー株式会社	ピモベンダン経口投与製剤
EP1920785A1 (en) *	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Liquid preparation comprising a complex of pimobendan and cyclodextrin
GB0818473D0 (en)	2008-10-08	2008-11-12	Probio Nutraceuticals As	Composition
WO2010055119A2 (en) *	2008-11-17	2010-05-20	Novartis Ag	Pharmaceutical composition comprising pimobendan
DK2370070T3 (da)	2008-11-25	2013-12-02	Boehringer Ingelheim Vetmed	Pimobendan til anvendelse i behandling af hypertrofisk cardiomyopati hos katte
NL1037569C2 (en)	2009-12-18	2011-06-21	Eurovet Animal Health B V	Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
AU2012296925A1 (en)	2011-08-12	2014-02-06	Boehringer Ingelheim Vetmedica Gmbh	Taste masked pharmaceutical composition
PL2793866T5 (pl)	2011-12-21	2023-12-04	Elanco Tiergesundheit Ag	Tabletka dwuwarstwowa zawierająca chlorowodorek benazeprylu i pimobendan
EP2825159B1 (en) *	2012-03-15	2022-06-22	Boehringer Ingelheim Vetmedica GmbH	Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2013135853A1 (en) *	2012-03-15	2013-09-19	Boehringer Ingelheim Vetmedica Gmbh	Pharmaceutical packaging product for the veterinary medical sector
AU2013361760B2 (en)	2012-12-19	2018-07-05	Elanco Animal Health Gmbh	Tablets with improved acceptance and good storage stability
SI3865120T1 (sl)	2013-07-19	2025-12-31	Boehringer Ingelheim Vetmedica Gmbh	Konzervirani eterificirani derivati ciklodekstrina, ki vsebujejo tekoč vodni farmacevtski sestavek
BR112016011111B1 (pt)	2013-12-04	2022-11-16	Boehringer Ingelheim Vetmedica Gmbh	Composições farmacêuticas aprimoradas de pimobendan
DK3389638T3 (da)	2015-12-17	2023-11-06	Ceva Sante Animale	Farmaceutisk sammensætning omfattende pimobendan
US10537570B2 (en)	2016-04-06	2020-01-21	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN106729723A (zh) *	2016-11-21	2017-05-31	青岛农业大学	一种含匹莫苯丹的药物组合物及其制备方法
KR102116712B1 (ko) *	2017-12-22	2020-05-29	주식회사 고려비엔피	기호성이 증진된 경구 투여 제제를 포함하는 개과 동물의 이첨판 판막 변성증 치료 또는 증상 완화용 제제
EP4034099A4 (en) *	2019-10-23	2023-10-25	Piedmont Animal Health Inc.	Pimobendan formulation and method of use thereof
CN120282774A (zh)	2022-12-15	2025-07-08	勃林格殷格翰动物保健有限公司	包含无定形匹莫苯丹及一种或多种稳定聚合物的固体分散体
CN121218995A (zh)	2023-05-24	2025-12-26	勃林格殷格翰动物保健有限公司	包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防
JP7659339B1 (ja)	2023-11-21	2025-04-09	東海カプセル株式会社	ピモベンダンを含有する経口フィルム製剤

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8101067A1 (es)	1978-08-25	1980-12-01	Thomae Gmbh Dr K	Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
JPS5636911A (en) *	1979-09-05	1981-04-10	Aisin Seiki	Mechanism for adjusting headrest
DE3237575A1 (de) *	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
DE3346123A1 (de)	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) *	1984-01-13	1984-02-15	Smith Kline French Lab	Chemical compounds
US6407079B1 (en) *	1985-07-03	2002-06-18	Janssen Pharmaceutica N.V.	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
ES2031821T3 (es) *	1985-10-17	1993-01-01	Smith Kline & French Laboratories Limited	Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
ZA878182B (en)	1986-11-05	1988-05-02	Merrell Dow Pharmaceuticals Inc.	Enhancement of prazosin
US4868182A (en) *	1986-11-05	1989-09-19	Merrell Dow Pharmaceuticals Inc.	Enhancement of prazosin
DE3728244A1 (de)	1987-08-25	1989-03-09	Thomae Gmbh Dr K	Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de)	1987-09-11	1990-05-02	Dr. Karl Thomae GmbH	Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5002935A (en) *	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) *	1988-02-12	1989-08-24	Heumann Pharma Gmbh & Co	Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de)	1988-02-24	1989-09-07	Thomae Gmbh Dr K	Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
IE62095B1 (en)	1988-03-29	1994-12-14	Univ Florida	Pharmaceutical formulations for parenteral use
ES2058503T5 (es)	1988-03-29	1999-04-16	Univ Florida	Formulaciones farmaceuticas para uso parenteral.
GB8824458D0 (en) *	1988-10-19	1988-11-23	Orion Yhtymae Oy	Substituted pyridazinones
GB8903130D0 (en)	1989-02-11	1989-03-30	Orion Yhtymae Oy	Substituted pyridazinones
US5364646A (en) *	1990-01-10	1994-11-15	Dr. Karl Thomae Gmbh	Oral pharmaceutical forms of pimobendan
DE4001622A1 (de)	1990-01-20	1991-07-25	Thomae Gmbh Dr K	Orale arzneimittelformen von pimobendan
DE4001623A1 (de) *	1990-01-20	1991-07-25	Thomae Gmbh Dr K	Verwendung von benzimidazolen zur herstellung eines zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen geeigneten arzneimittels
GB2251615B (en) *	1991-01-03	1995-02-08	Orion Yhtymae Oy	(-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH0570612A (ja)	1991-09-12	1993-03-23	Toyobo Co Ltd	二軸配向ポリエステルフイルム
EP0760648B1 (en) *	1994-05-20	2001-11-14	Janssen Pharmaceutica N.V.	Chewable flubendazole tablets for companion animals
JPH11228302A (ja)	1998-02-18	1999-08-24	Taisho Technos Co Ltd	抗菌防黴組成物
US6476078B2 (en) *	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6369087B1 (en) *	1999-08-26	2002-04-09	Robert R. Whittle	Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
DE60124504T2 (de) *	2000-02-04	2007-09-20	Takeda Pharmaceutical Co. Ltd.	Stabile emulsionszubereitungen
US7727548B2 (en)	2000-03-01	2010-06-01	Eisai R&D Management Co., Ltd.	Rapidly disintegrable tablet containing polyvinyl alcohol
WO2001097861A2 (en)	2000-06-21	2001-12-27	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
EP2266549B1 (en) *	2000-06-27	2019-08-07	Vectura Limited	Method of making particles for use in a pharmaceutical composition
UA80393C2 (uk) *	2000-12-07	2007-09-25	Алтана Фарма Аг	Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CN1461218A (zh)	2000-12-18	2003-12-10	诺瓦提斯公司	阿洛地平和贝那普利的治疗组合
EP1247456A3 (en) *	2001-02-28	2003-12-10	Pfizer Products Inc.	Palatable pharmaceutical compositions for companion animals
EP1363631A4 (en)	2001-03-02	2005-11-16	Bristol Myers Squibb Co	"COMPOUNDS SUITED AS MODULATORS OF MELANOCORTIN RECEPTORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF"
ATE481497T1 (de)	2001-08-01	2010-10-15	Univ Utah	Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US20030190343A1 (en) *	2002-03-05	2003-10-09	Pfizer Inc.	Palatable pharmaceutical compositions for companion animals
DE10209982A1 (de) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
PE20040468A1 (es)	2002-05-17	2004-09-14	Novartis Ag	Combinacion de compuestos organicos
CN1655820A (zh)	2002-05-23	2005-08-17	辉瑞大药厂	Pde5抑制剂与ace抑制剂的药物组合
DE10228049A1 (de)	2002-06-24	2004-01-15	Merck Patent Gmbh	Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en)	2002-08-16	2004-02-26	Douglas Cleverly	Non-animal product containing veterinary formulations
EP1554267A1 (en)	2002-10-07	2005-07-20	Artesian Therapeutics, Inc.	Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity
US20070060748A1 (en)	2002-11-27	2007-03-15	Hamilton Gregory S	Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
EP1575923A2 (en)	2002-12-23	2005-09-21	Artesian Therapeutics, Inc.	CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST &bgr;-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
WO2005035505A2 (en)	2003-09-30	2005-04-21	Artesian Therapeutics, Inc.	Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) *	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP2005281283A (ja)	2004-03-31	2005-10-13	Akira Matsumori	ベンズイミダゾール系薬剤の併用医薬
FI20040675A0 (fi)	2004-05-12	2004-05-12	Orion Corp	Menetelmä sydämen hypertrofian hoitoon ja estoon
NZ534939A (en)	2004-08-26	2007-04-27	Bomac Research Ltd	Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
WO2006060127A2 (en)	2004-11-30	2006-06-08	Artesian Therapeutics, Inc.	COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
EP1833480A2 (en)	2004-11-30	2007-09-19	Artesian Therapeutics, Inc.	Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
CN1702243A (zh)	2005-05-31	2005-11-30	刘坚雄	无壁板框架结构装配组合式房屋建筑及其建造方法
EP1903039A4 (en)	2005-06-13	2010-09-22	Takeda Pharmaceutical	INJECTION
EP1951227B1 (en)	2005-11-14	2017-04-12	Boehringer Ingelheim Vetmedica GmbH	Use of pimobendan for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Liquid preparation comprising a complex of pimobendan and cyclodextrin
DK2370070T3 (da)	2008-11-25	2013-12-02	Boehringer Ingelheim Vetmed	Pimobendan til anvendelse i behandling af hypertrofisk cardiomyopati hos katte

2004
- 2004-03-08 DE DE102004011512.5A patent/DE102004011512B4/de not_active Expired - Lifetime
2005
- 2005-03-01 EP EP05715625.9A patent/EP1725218B1/en not_active Expired - Lifetime
- 2005-03-01 AU AU2005218912A patent/AU2005218912C1/en not_active Expired
- 2005-03-01 PT PT14171534T patent/PT2783682T/pt unknown
- 2005-03-01 NZ NZ549630A patent/NZ549630A/en not_active IP Right Cessation
- 2005-03-01 IN IN7624DEN2014 patent/IN2014DN07624A/en unknown
- 2005-03-01 KR KR1020067020830A patent/KR20070014143A/ko not_active Ceased
- 2005-03-01 BR BRPI0508557A patent/BRPI0508557B1/pt active IP Right Grant
- 2005-03-01 PL PL14171534T patent/PL2783682T3/pl unknown
- 2005-03-01 SI SI200531881T patent/SI1725218T1/sl unknown
- 2005-03-01 MX MXPA06009889A patent/MXPA06009889A/es active IP Right Grant
- 2005-03-01 KR KR1020117031245A patent/KR101290077B1/ko not_active Expired - Lifetime
- 2005-03-01 ES ES05715625.9T patent/ES2501216T3/es not_active Expired - Lifetime
- 2005-03-01 JP JP2007501196A patent/JP4757253B2/ja not_active Expired - Lifetime
- 2005-03-01 PL PL05715625T patent/PL1725218T3/pl unknown
- 2005-03-01 DK DK14171534.2T patent/DK2783682T3/da active
- 2005-03-01 SI SI200532259T patent/SI2783682T1/sl unknown
- 2005-03-01 CN CNB2005800075878A patent/CN100546568C/zh not_active Expired - Lifetime
- 2005-03-01 WO PCT/EP2005/002133 patent/WO2005084647A1/en not_active Ceased
- 2005-03-01 ES ES14171534T patent/ES2736022T3/es not_active Expired - Lifetime
- 2005-03-01 DK DK05715625.9T patent/DK1725218T3/da active
- 2005-03-01 CA CA2557161A patent/CA2557161C/en not_active Expired - Lifetime
- 2005-03-01 HR HRP20140900TT patent/HRP20140900T1/hr unknown
- 2005-03-01 HU HUE14171534A patent/HUE045637T2/hu unknown
- 2005-03-01 PT PT57156259T patent/PT1725218E/pt unknown
- 2005-03-01 EP EP14171534.2A patent/EP2783682B1/en not_active Expired - Lifetime
- 2005-03-01 LT LTEP14171534.2T patent/LT2783682T/lt unknown
- 2005-03-04 AR ARP050100830A patent/AR047993A1/es not_active Application Discontinuation
- 2005-03-04 US US11/072,207 patent/US8846679B2/en active Active
- 2005-03-07 TW TW094106822A patent/TWI355947B/zh not_active IP Right Cessation
2006
- 2006-07-25 ZA ZA200606154A patent/ZA200606154B/xx unknown
2011
- 2011-02-03 JP JP2011021706A patent/JP5875231B2/ja not_active Expired - Lifetime
2012
- 2012-02-22 US US13/402,292 patent/US8846680B2/en not_active Expired - Lifetime
2013
- 2013-03-14 US US13/802,989 patent/US8859554B2/en not_active Expired - Lifetime
2014
- 2014-08-21 US US14/465,273 patent/US20140363510A1/en not_active Abandoned
- 2014-09-03 CY CY20141100704T patent/CY1115526T1/el unknown
2016
- 2016-11-30 AR ARP160103652A patent/AR106850A2/es not_active Application Discontinuation
2017
- 2017-09-05 US US15/695,334 patent/US20170368062A1/en not_active Abandoned
2019
- 2019-07-26 HR HRP20191360 patent/HRP20191360T1/hr unknown
- 2019-08-08 CY CY20191100849T patent/CY1121877T1/el unknown

Also Published As

Publication number	Publication date
AR106850A2 (es)	2018-02-21
JP5875231B2 (ja)	2016-03-02
EP2783682B1 (en)	2019-05-22
US8859554B2 (en)	2014-10-14
KR20070014143A (ko)	2007-01-31
JP2007526269A (ja)	2007-09-13
DE102004011512A1 (de)	2005-09-22
ES2501216T3 (es)	2014-10-01
US8846680B2 (en)	2014-09-30
DE102004011512B4 (de)	2022-01-13
PT2783682T (pt)	2019-09-10
JP4757253B2 (ja)	2011-08-24
IN2014DN07624A (da)	2015-07-10
US20120148640A1 (en)	2012-06-14
HUE045637T2 (hu)	2020-01-28
SI2783682T1 (sl)	2019-08-30
TW200539901A (en)	2005-12-16
CN100546568C (zh)	2009-10-07
PT1725218E (pt)	2014-09-03
CN1929821A (zh)	2007-03-14
EP2783682A1 (en)	2014-10-01
MXPA06009889A (es)	2007-11-20
CA2557161C (en)	2013-06-25
US20170368062A1 (en)	2017-12-28
AR047993A1 (es)	2006-03-15
HRP20191360T1 (hr)	2019-11-01
WO2005084647A1 (en)	2005-09-15
ZA200606154B (en)	2007-11-28
CY1115526T1 (el)	2017-01-04
AU2005218912B2 (en)	2010-09-16
SI1725218T1 (sl)	2014-09-30
DK1725218T3 (da)	2014-09-01
TWI355947B (en)	2012-01-11
PL1725218T3 (pl)	2014-11-28
US8846679B2 (en)	2014-09-30
CA2557161A1 (en)	2005-09-15
US20130177613A1 (en)	2013-07-11
US20050203097A1 (en)	2005-09-15
BRPI0508557A (pt)	2007-08-07
US20140363510A1 (en)	2014-12-11
LT2783682T (lt)	2019-07-25
NZ549630A (en)	2009-07-31
EP1725218A1 (en)	2006-11-29
KR101290077B1 (ko)	2013-08-01
KR20120006089A (ko)	2012-01-17
BRPI0508557B1 (pt)	2018-12-18
ES2736022T3 (es)	2019-12-23
EP1725218B1 (en)	2014-06-25
AU2005218912A1 (en)	2005-09-15
HRP20140900T1 (hr)	2014-11-07
JP2011098977A (ja)	2011-05-19
CY1121877T1 (el)	2020-10-14
AU2005218912C1 (en)	2012-10-25
PL2783682T3 (pl)	2019-11-29

Publication	Publication Date	Title
DK2783682T3 (da)	2019-08-12	Farmaceutisk sammensætning omfattende pimobendan
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
DK1884242T3 (da)	2013-05-06	Farmaceutisk sammensætning omfattende lurasidon
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
EP1788047A4 (en)	2011-12-21	WATER REPELLENT / OIL-REPELLING COMPOSITION
CY2014030I1 (el)	2020-05-29	Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
ITMI20041252A1 (it)	2004-09-22	Composizioni perfluoroelastomeriche
BRPI0613033A2 (pt)	2016-11-29	composição oral
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
NO20055686D0 (no)	2005-12-01	Sammensetning
MA28801B1 (fr)	2007-08-01	Composition antihistaminique
DE602005020716D1 (de)	2010-06-02	Fluoroelastomere
DK1957073T3 (da)	2014-05-12	Lægemiddel
DE602005016978D1 (de)	2009-11-12	Quecksilberfreisetzende Zusammensetzungen
DE602005017191D1 (de)	2009-11-26	Geruchsreduzierte waschstück-zusammensetzung
FR2871686B1 (fr)	2008-02-29	Composition anti-decoloration
ITMI20041447A1 (it)	2004-10-20	Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it)	2004-08-11	Composizione farmaceutica cicatrizzante
NO20042027D0 (no)	2004-05-14	Oral composition
DK1753431T3 (da)	2009-11-16	Farmaceutisk sammensætning omfattende ZD6474
SE0400205D0 (sv)	2004-02-02	Composition
ITMI20061734A1 (it)	2008-03-12	Composizione farmaceutica